Six-Month Clinical Outcome of Cyclosporine Microemulsion Formulation (Sigmasporin Microral) in Stable Renal Transplant Patients Previously Maintained on Sandimmun Neoral

Transplantation Proceedings

Volumn 40, Issue 7, 2008, Pages 2245-2251

  Al Wakeel, J S ^a   Shaheen, F A M ^b   Mathew, M C ^c   Abou Zeinab, H M ^d   Al Alfi, A ^e   Tarif, N M ^a   Al Mousawi, M S A ^f   Mahmoud, T S ^f   Alorrayed, A S ^g   Fagir, E A ^h   Dham, R S ⁱ   Shaker, D S ⁱ  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b Saudi Center for Organ Transplantation   (Saudi Arabia)

^c Al Qassimi Hospital   (United Arab Emirates)

^d Hammoud Academic Medical Center   (Lebanon)

^e King Abdulaziz Hosp and Oncology Centre   (Saudi Arabia)

^f IBN SINA HOSPITAL   (Kuwait)

^g Salmaniya Hospital   (Bahrain)

^h IBHO and SBG Hospitals ^*  (United Arab Emirates)

ⁱ Dubai Research Center   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; AZATHIOPRINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SIGMASPORIN MICRORAL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HIRSUTISM; HUMAN; HYPERPLASIA; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SURVIVAL; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 51249111984     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.06.044     Document Type: Article

References (67)

1. Moosa M.R., Walele A.A., and Daar A.S. Renal transplantation in developing countries. In: Morris P.B. (Ed). Kidney transplantation: principles and practice (2001), W.B. Saunders, Philadelphia 659
2. Ota B., and Bradley M. Side effects of cyclosporine in 100 renal allograft recipients. Transplant Proc 1 suppl (1983) 3150
3. Calne R.Y., Alexandre G.P., and Murray J.E. A study of the effects of drugs in prolonged survival of homologous renal transplantation in dogs. Ann NY Acad Sci 99 (1962) 743
4. Lindholm A., Henricsson S., Lind M., et al. Intra individual variability in the relative systemic availability of cyclosporine after oral dosing. Eur J Clin Pharmacol 34 (1998) 461
5. Kahan B.D. Cyclosporine. N Engl J Med 321 (1989) 1725
6. Lemaire M., Fahr A., and Maurer G. Pharmacokinetics of cyclosporine: inter- and intra individual variation and metabolic pathways. Transplant Proc 22 (1990) 1110
7. Fahr A. Cyclosporine clinical pharmacokinetics. Clin Pharmacokinet 24 (1993) 472
8. Gupta S.K., Manfro R.C., Tomlanovich S.J., et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 30 (1990) 643
9. Korvarik J.M., Mueller E.A., van Bree J.B., et al. Cyclosporine pharmacokinetics and variability from a micro- emulsion formulation-a multicenter investigation in kidney transplant recipients. Transplantation 58 (1994) 658
10. Levy G., Rochon J., Freeman D., et al. Cyclosporine Neoral in liver transplant recipients. Transplant Proc 26 (1994) 2949
11. Trull A.K., Tan K.K.C., Uttidge J., et al. Cyclosporine absorption from microemulsion formulation in liver transplant recipients. Lancet 345 (1995) 1644
12. Ferrea G., Fioredda F., Loy A., et al. Oral microemulsion formulation substitutes for intravenous cyclosporine in child with graft-versus-host disease. Lancet 344 (1994) 480
13. Lindholm A., Dahlqvist R., Groth G.G., et al. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 30 (1990) 443
14. Neumayer H.H., Farber L., Haller P., et al. Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts. Results after one month. Transplant Proc 84 (1994) 2944
15. Lindhol A., and Kahan B.D. Cyclosporine. Clin Pharmacol Ther 54 (1993) 205
16. Kasiske B.L., Cohen D., Lucey M.R., et al. Payment for immunosuppression after organ transplantation. JAMA 383 (2000) 2445
17. Didlake R.H., Dreyfus K., Kerman R.H., et al. Patients' noncompliance: a major cause of late graft failure in cyclosporine treated renal transplants. Transplant Proc 20 (1988) 63
18. Kiley D.J., Lam C.S., and Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 55 (1993) 51
19. Frazier P.A., Davis Ali S.H., and Dahl K.E. Correlates of noncompliance among renal transplant recipients. Clin Transplant 8 (1994) 550
20. Bergmann L.S., Roper L., Bow L.M., et al. Causes of late graft failure in cadaveric renal transplantation. Transplant Proc 25 (1993) 1340
21. Sketris I., Waite N., Grobler K., et al. Factors affecting compliance with cyclosporine in adult renal transplant patients. Transplant Proc 26 (1994) 2538
22. De Geest S., Borgermans L., Gemoets H., et al. Incidence, determinants, and consequences of sub-clinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 59 (1995) 340
23. Greenstein S., and Siegal B. Compliance and noncompliance in patients with functioning renal transplant: a multicenter study. Transplantation 66 (1998) 1718
24. Hilbrands L.B., Hoitsma A.J., and Koene R.A.P. Medication compliance after renal transplantation. Transplantation 60 (1995) 914
25. Butkus D.E., Meydrech E.F., and Raju S.S. Radical differences in the survival of cadaveric renal allografts: over riding effects of HLA matching and socioeconomic factors. N Engl J Med 327 (1992) 840
26. Rovelli M., Palmeri D., Vossier E., et al. Noncompliance in renal transplant recipients: evaluation by socioeconomic groups. Transplant Proc 21 (1989) 3979
27. Approved drug products with therapeutic equivalence evaluations. 17th ed. (1997), EHHS/Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD
28. Degiorgio V., Piazza R., and Oliani C. Characterization of microemulsion: a dynamic light scattering investigation of Cyclosporine-A preparations. Acta Technologiae et Legis Medicamenti 9 (1998) 133
29. Tanasescu C., Serbanescu A., Spadaro A., et al. Comparison of two microemulsion of cyclosporine A in healthy volunteers. European Review for Medical and Pharmacological Sciences 3 (1999) 5
30. Single dose, open label, two way treatment, two way crossover comparative bioavailability study of Sigmasporin Microral 100mg soft gelatin capsule and Sandimmun Neoral 100mg soft gelatin capsule in healthy human subjects under fasting and fed conditions. Data on file. Sante-Foy, Quebec, Canada: Anapharm and Allied Clinical Research, November 2002
31. Sineschu I., Vasconcellos L.H., Foschi D., et al. New cyclosporine microemulsion randomized bioequivalence steady-state study in renal transplanted patients. European Review for Medical and Pharmacological Sciences 3 (1999) 11
32. Olej B., Lugon J.R., et al. Immunosuppressive activity of cyclosporine A formulations in mononuclear cells. Braz J Nephrol 24 suppl IA (2002) 9
33. Elisa G., Mendes F., and Emmanuel A. A comparison between the experimental nephrotoxicity of two cyclosporine A microemulsion formulations. Braz J Nephrol 24 suppl IA (2002) 31
34. de Mello V.R., Guersoni A.C., et al. Cyclosporine in treatment of steroid resistant and steroid dependent idiopathic nephritic syndrome. Braz J Nephrol 24 suppl IA (2002) 19
35. Manrique R., Magalhaes H.M., Dinhuysen J., et al. Clinical pharmacokinetic comparison between microemulsion formulations of cyclosporine A in heart transplant patients. Braz J Nephrol 24 suppl IA (2002) 45
36. Assbu M.S., Magalhaes M.V., Cruz C., et al. Conversion of Sandimmun Neoral to Sigmasporin Microral in stable renal transplant patients. Braz J Nephrol 23 suppl 2 (2001) 8
37. Najib N.M., Idkaidek N., Adel A., et al. Comparison of two cyclosporine formulations in healthy Middle Eastern volunteers: bioequivalence of the new Sigmasporin Microral and Sandimmun Neoral. European Journal of Pharmaceutics and Biopharmaceutics 55 (2003) 67
38. Therapeutic equivalence and mg:mg switchability of a generic cyclosporine A microemulsion (Sigmasporin Microral) in stable renal transplant patients. Open, multiple- fixed dose, one way cross-over, multicenter, and multi national study in 4 Middle Eastern countries. Transplant Proc (in press)
39. 2 monitoring of cyclosporine microemulsion. Transplantation 76 (2003) 903
40. Montagnino G., Tarantino A., Maccano M., et al. Long term results with cyclosporine monotherapy in renal transplant patients: A multivariate analysis of risk factor. Am J Kidney Dis 35 (2000) 1135
41. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713
42. di Paolo S., Teutonico A., Stallone G., et al. Cyclosporine exposure correlates with 1-year graft function and histological damage in renal transplant patients. Nephrol Dial Transplant 19 (2004) 2107
43. Gavin III J.R. New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone 1 (1998) 1
44. Jindal R.M., and Hjelmesaeth J. Impact and management of post transplant diabetes mellitus. Transplantation 70 (2000) S58
45. Chow S.C., Shao J., and Wang H. Sample size calculation in clinical research (2003), Marcel Dekker, New York
46. Machin D., Campbell M., Fayers P., et al. Sample size tables for clinical studies. 2nd ed. (1997), Blackwell Science, Malden, MA
47. Burke J.F., Pirsch J.D., Ramos E., et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 331 (1994) 358
48. Almond P.S., Matas A., Gillingham K., et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 55 (1993) 752
49. Kahan B.D., Welsh M., Schoenberg L., et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62 (1996) 599
50. Kovarik J.M., Mueller E.A., Richard F., et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 62 (1996) 759
51. Kahan B.D., Dunn J., Fitts C., et al. Reduced inter- and intra subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 59 (1995) 505
52. Bokenkamp A., Offner G., Hoyer P.F., et al. Improved absorption of cyclosporine A from a new microemulsion formulation: Implications for dosage and monitoring. Pediatr Nephrol 9 (1995) 196
53. Wahlberg J., Wilczek H.E., Fauchald P., et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 60 (1995) 648
54. Barone G., Chang C.T., Choc M.G.J., et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients: The Neoral Study Group. Transplantation 61 (1996) 875
55. Pollak R., Wong R.L., and Chang C.T. Cyclosporine bioavailability of Neoral and Sandimmun in white and black de novo renal transplant recipients: Neoral Study Group. Ther Drug Monit 21 (1999) 661
56. Gaston R.S., Hudson S.L., Ward M., et al. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 31 suppl 4A (1999) 21S
57. Halloran P.F., Helms L.M., Kung L., et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68 (1999) 1356
58. Johnston A., Belitsky P., Frei U., et al. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Pharmacol 60 (2004) 389
59. Grevel J., Napoli K.L., and Kahan B.D. Co variables in cyclosporine immunosuppression. Transplant Proc 22 (1990) 1113
60. Yee G.C., and McGuire T.R. Pharmacokinetic drug interaction with cyclosporine (part II). Clin Pharmacokinet 19 (1990) 400
61. Pascual J., Quereda C., Zamora C., et al. Steroid withdrawal in renal transplant patients on triple therapy with calcineurin inhibitor and mycophenolate mofetil: a meta- analysis of randomized, controlled trials. Transplantation 78 (2004) 1548
62. Shah M.B., Martin J.E., Schroeder T.J., et al. Evaluation of the safety and tolerability of Neoral and Sandimmun: meta-analysis. Transplant Proc 30 (1998) 1697
63. De Mattos A.M., Olyaei A.J., and Bennett W.M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 35 (2000) 333
64. Dunn C.J., Wagstaff A.J., Perry C.M., et al. Cyclosporine: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion based formulation (Neoral) in organ transplantation. Drugs 61 (2001) 1957
65. Cole E., Keown P., Landsberg D., et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of fellow up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. Transplantation 65 (1998) 505
66. First M.R., Gerber D.A., Hariharan S., et al. Post transplantation diabetes mellitus in kidney allograft recipients: incidence, risk factor and management. Transplantation 73 (2002) 379
67. Adeghate E., Schattner P., and Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 1084 (2006) 1